‘High risk’ clinical and inflammatory clusters in COPD of Chinese descent by Tiew, PY et al.
Word count main body: 3,367 (Abstract 233) 1 
 2 
‘HIGH RISK’ CLINICAL AND INFLAMMATORY CLUSTERS IN COPD OF 3 
CHINESE DESCENT 4 
Pei Yee Tiew, MD1,2, Fanny Wai San Ko, MD3, Jayanth Kumar Narayana, BS-MS1,4, Mau Ern 5 
Poh, MD5, Huiying Xu, MD6, Han Yee Neo, MD6, Li-Cher Loh, MD7, Choo-Khoo Ong, MD7, 6 
Micheál Mac Aogáin, PhD1, Jessica Han Ying Tan, MD8, Nabilah Husna Kamaruddin5, Gerald 7 
Jiong Hui Sim9, Therese S. Lapperre, MD, PhD2,10, Mariko Siyue Koh, MD2, David Shu 8 
Cheong Hui, MD3, John Arputhan Abisheganaden, MD6, Augustine Tee, MD9, Krasimira 9 
Tsaneva-Atanasova, PhD11,12, Sanjay H. Chotirmall, MD, PhD1#. 10 
 11 
1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore  12 
2Department of Respiratory and Critical Care Medicine, Singapore General Hospital, 13 
Singapore 14 
3Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong 15 
Kong 16 
4Indian Institute of Science Education and Research, Pune, India 17 
5Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia 18 
6Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore  19 
7Department of Medicine, RCSI-UCD Malaysia Campus, Georgetown, Penang, Malaysia 20 
8Department of General Medicine, Sengkang General Hospital, Singapore 21 
9Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore 22 
10Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark 23 
11Living Systems Institute and Department of Mathematics, College of Engineering, 24 
Mathematics and Physical Sciences, University of Exeter 25 
12PSRC Centre for Predictive Modelling in Healthcare, University of Exeter 26 
 27 
# Corresponding author: Sanjay H. Chotirmall, Lee Kong Chian School of Medicine, 28 




Running head: 33 
COPD in Chinese patients exhibits clinical-inflammatory clustering where ‘cardiovascular’ 34 
and ‘ex-tuberculosis’ groups illustrate highest mortality. Risk stratification of Chinese patients 35 
with COPD is necessary for targeted intervention. 36 
 37 
Conflict of interest: All authors have no conflicts of interest to declare. 38 
 39 
Funding: This research is supported by the Singapore Ministry of Health’s National Medical 40 
Research Council under its Research Training Fellowship (NMRC/Fellowship/0049/2017) 41 
(P.Y.T) and a Clinician-Scientist Individual Research Grant (MOH-000141) (S.H.C); the 42 
Singapore Ministry of Education under its Singapore Ministry of Education Academic 43 
Research Fund Tier 1 (2016-T1-001-050) (S.H.C); the NTU Integrated Medical, Biological 44 
and Environmental Life Sciences (NIMBELS), Nanyang Technological University, Singapore 45 
[NIM/03/2018] (S.H.C) and the Ageing Research Institute for Society and Education (ARISE), 46 
Nanyang Technological University, Singapore [ARISE/2017/6] (S.H.C). KTA gratefully 47 
acknowledges the financial support of the EPSRC via grant EP/N014391/1.  48 
 49 
Parts of this article have been presented in the form of an abstract at the European Respiratory 50 







Abbreviation List 58 
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Abstract  83 
Introduction: COPD is a heterogeneous disease demonstrating inter-individual variation. A 84 
high COPD prevalence in Chinese populations is described but little is known about disease 85 
clusters and prognostic outcomes in the Chinese population across South-East Asia. We aim to 86 
determine if clusters of Chinese patients with COPD exist and their association with systemic 87 
inflammation and clinical outcomes. Methods: Chinese patients with stable COPD were 88 
prospectively recruited into two cohorts (derivation and validation) from six hospitals across 89 
three South-East Asian countries (Singapore, Malaysia and Hong Kong; n=1,480). Each patient 90 
was followed over two-years. Clinical data (including co-morbidities) were employed in 91 
unsupervised hierarchical clustering (followed by validation) to determine the existence of 92 
patient clusters and their prognostic outcome. Accompanying systemic cytokine assessments 93 
were performed in a subset (n=336) of COPD patients to determine if inflammatory patterns 94 
and associated networks characterised the derived clusters. Results: Five patient clusters were 95 
identified including (1) Ex-tuberculosis (2) Diabetic (3) Low co-morbidity: low-risk (4) Low 96 
co-morbidity: high-risk and (5) cardiovascular. The ‘cardiovascular’ and ‘ex-tuberculosis’ 97 
clusters demonstrate highest mortality (independent of GOLD assessment) and illustrate 98 
diverse cytokine patterns with complex inflammatory networks. Conclusions: We describe 99 
novel ‘clusters’ of Chinese COPD patients, two of which represent ‘high-risk’ clusters. The 100 
‘cardiovascular’ and ‘ex-tuberculosis’ patient clusters exhibit high mortality, significant 101 
inflammation and complex cytokine networks. Clinical and inflammatory risk stratification of 102 
Chinese patients with COPD should be considered for targeted intervention to improve disease 103 
outcomes.  104 
 105 
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 107 
Introduction 108 
Chronic obstructive pulmonary disease (COPD) in the Asian sub-continent is under-estimated 109 
owing to poor disease awareness and significantly delayed diagnosis 1-2. COPD burden in Asia 110 
is expected to further increase, driven by ageing populations, increased tobacco consumption 111 
and rapid urbanization 3-5.  112 
 113 
While an inimitable group of COPD-associated risk factors exists in Asia, a diverse range of 114 
geographic environments, climates, cultural practices, healthcare policies and resource 115 
availability influences diagnosis and management 6. Taken together, this contributes to 116 
clinically different COPD phenotypes in the region, for instance, higher males, non-smokers 117 
and less symptoms compared to western cohorts 7-8. Prior work focused on racial differences 118 
includes few Asian-based patients and is predominantly conducted outside Asia 9-11.  119 
 120 
More recently, work on ethnic Chinese populations reveals the prevalence and scale of COPD 121 
12. The China Pulmonary Health study evaluated a nationally representative sample of adults 122 
across mainland China. Of the 57,779 individuals studied, COPD prevalence was 8.6%, 123 
accounting for almost 100 million individuals, a clear public health priority 12. A second study 124 
involving 67,752 Chinese adults confirms these findings and estimates COPD burden at 13.6% 125 
1. Because of large COPD numbers, it is plausible that disease ‘sub-groups’ with differing 126 
prognostic outcomes exist necessitating individualized intervention. Significant numbers of 127 
ethnically Chinese individuals reside in countries across the Asian sub-continent including 128 
Malaysia, Singapore and Hong Kong and little published data has assessed COPD in these 129 
populations. The limited data does however suggest high mortality in Chinese COPD patients 130 
13.  131 
In view of high COPD burden and mortality in Chinese patients, a need to better understand 132 
potential disease clusters (or sub-groups) exists to allow improved risk stratification and 133 
targeted intervention. Here, in a multi-centre study across three countries in South-East Asia, 134 
we evaluate a large group of Chinese patients with COPD and describe clusters with prognostic 135 
and inflammatory relevance. 136 
 137 
Methods 138 
COPD patient recruitment:  Patients of Chinese ethnicity (defined as an individual where both 139 
parents were of Chinese lineage) aged ≥40 with stable COPD as their predominant diagnosis 140 
were prospectively recruited over a seven-year period from January 2012 – December 2018 141 
when attending respiratory outpatient clinics at six tertiary hospital sites across three countries: 142 
(1) Singapore (3 sites: Singapore General Hospital, Changi General Hospital and Tan Tock 143 
Seng Hospital); (2) Malaysia (2 sites: RCSI-UCD Malaysia Campus and University Malaya 144 
Hospital) and (3) Hong Kong (1 site: Prince of Wales Hospital). COPD was defined according 145 
to the global initiative for chronic obstructive lung disease (GOLD) criteria 14. Bronchiectasis 146 
was excluded by chest radiography in the absence of tram tracking, ring opacities and tubular 147 
structures15-16. Disease stability was defined as the absence of exacerbation over the preceding 148 
six weeks prior to study recruitment and all patients were receiving COPD therapy (including 149 
smoking cessation counseling, inhaler assessment, COPD action plans, inhalers as long acting 150 
β-agonists, long acting muscarinic antagonists, inhaled corticosteroids and/or short acting 151 
bronchodilators in addition to vaccination as appropriate) based on GOLD guidelines14.  152 
 153 
 154 
Derivation and Validation COPD cohorts: A complete cohort of n=1,480 COPD patients of 155 
Chinese ethnicity were recruited into the study in two separate arms: a derivation and validation 156 
cohort. A total of n=911 patients made up the derivation cohort and were recruited from four 157 
different sites over the study period from 2012: Singapore General Hospital and Changi 158 
General Hospital (Singapore), RCSI-UCD Malaysia Campus (Malaysia) and Prince of Wales 159 
Hospital (Hong Kong). An independent and unrelated validation cohort of n=569 patients were 160 
recruited from five different sites from 2013 onward: Singapore General Hospital, Tan Tock 161 
Seng Hospital, Changi General Hospital (Singapore), University Malaya Hospital (Malaysia) 162 
and Prince of Wales Hospital (Hong Kong). Clinical data was obtained for all subjects and the 163 
institutional review board of all participating hospitals approved the study.  164 
 165 
Clustering analysis: Clinical variables and comorbidities were pre-processed with non-metric 166 
multidimensional scaling followed by hierarchical clustering. A trained Regularised 167 
Discriminant Analysis model was used to assign cluster membership for the validation cohort. 168 
Each derived cluster was defined based on the predominant (or lack of) clinical features, 169 
comorbidities and outcome (mortality). 170 
 171 
Full details on ethical approvals, patient recruitment, clinical data collation, specimen 172 
collection and processing, inflammatory assessments and statistics are provided in the e-173 






Independent unrelated derivation (n=911) and validation (n=569) cohorts of Chinese patients 180 
with COPD were recruited. Demographic profiles between cohorts were comparable and 181 
similar proportions of patients (from each country) formed the final cohorts (e-Table 1). The 182 
majority of patients (in both cohorts) were male, and, while more current smokers and ex-183 
smokers were identified in the derivation and validation cohorts respectively (p<0.001), no 184 
significant difference in overall smoking pack years between cohorts was observed (e-Table 185 
1). Greater proportions of prior pulmonary tuberculosis (18.2% versus 8.4%; p<0.001), 186 
osteoporosis (3.7% versus 1.4%; p<0.01) and asthma (7.1% versus 1.9%; p<0.001) were 187 
identified in the derivation while more malignancy (8.0% versus 17.2%; p<0.001) detected in 188 
the validation cohort (e-Figure 1a). Prior pulmonary tuberculosis was highest in the Malaysian 189 
derivation and lowest in the Hong Kong validation cohort (p<0.001) reflective of contrasting 190 
TB prevalence (e-Figure 1b). Coronary artery disease was highest in both cohorts from 191 
Singapore while peptic ulcer disease was greatest in the Malaysian derivation and lowest in 192 
their validation cohort. Airway microbiology demonstrates more S. pneumoniae and H. 193 
influenzae in the derivation cohort (e-Figure 1c). 194 
 195 
Unsupervised hierarchical clustering of the derivation (n=911) cohort revealed five clusters of 196 
Chinese COPD each defined by their predominant (or lack of) clinical features: (1) prior 197 
pulmonary tuberculosis (Ex-TB; n=156); (2) co-existing diabetes (diabetic; n=109); (3) low 198 
co-morbidity: low risk (LCLR; n=192); (4) low-comorbidity: high risk (LCHR; n=339) and (5) 199 
co-existing cardiovascular disease (CVS; n=115) (Figure 1 and e-Table 2). While two clusters 200 
demonstrate low co-morbidity, the LCHR and CVS clusters closely resembled one another, 201 
separated only by dendrogram branching (Figure 1). Prognostic outcome between clusters 202 
varied based on two-year all cause and respiratory-related mortality (Figures 2a-c). Two-year 203 
mortality was highest in the CVS (42.6%), Ex-TB (34.0%) and LCHR (25.7%) clusters (log 204 
rank test, p<0.05) (Figure 2a), which remained significant after adjustment for age, sex, BMI, 205 
FEV1 and smoking pack year exposure (Figure 2b). Hazard ratio for death in each cluster 206 
(compared to LCLR) was as follows: CVS (HR: 2.94; 95% CI 1.51-5.72; p<0.01), Ex-TB (HR: 207 
2.10; 95% CI 1.16-3.80; p<0.05), LCHR (HR: 2.01; 95% CI 1.18-3.43; p=0.01) and diabetic 208 
(HR: 1.67; 95% CI 0.82-3.40; p=ns). When only respiratory-related causes of death are 209 
considered, a similar pattern (to that with all-cause mortality) is observed (Figure 2c). Smoking 210 
status had no influence on mortality (e-Figure 2a) or exacerbation severity (e-Figure 2b) within 211 
each cluster however did differ between the low co-morbidity clusters with predominantly 212 
current smokers in the LCHR and ex-smokers in the LCLR clusters (e-Table 2). 213 
 214 
Having identified five clinical clusters demonstrating different prognostic outcomes, we next 215 
validated these findings in an independently recruited validation cohort (n=569). All patients 216 
in the validation cohort were assigned to a cluster using Regularised Discriminant Analysis 217 
(RDA) with a high Leave One Out Cross Validation accuracy (97.8%) illustrating robustness 218 
of both our model and the previously derived clusters (e-Table 3 and e-Figure 3). The validation 219 
cohort was assigned as follows: Ex-TB (n=102; 17.9%), diabetic (n=72; 12.7%), LCLR (n=88; 220 
15.5%), LCHR (n=193; 33.9%) and CVS (n=114; 20.0%). The mean RDA assigned probability 221 
of a patient from the validation cohort belonging to each of the derived clusters is as follows:  222 
Ex-TB (mean 93% ± SD 13%), diabetic (mean 96% ± SD 8%), CVS (mean 99%± SD 6%), 223 
LCHR (mean 88%± SD 17%), and LCLR (mean 69%± SD 13%).  224 
 225 
Overall proportion of patients in each cluster was comparable to the derivation cohort despite 226 
a lower overall prevalence of co-morbidities (including TB) (e-Tables 2 and e-Table 4). 227 
Baseline co-morbidities (Figure 3) and two-year all-cause mortality followed the derivation 228 
cohort with poorest survival observed in the CVS (43.0%) and Ex-TB (26.0%) clusters (log 229 
rank test, p=0.001) (Figure 4a) which remained significant after adjustment for age, sex, BMI, 230 
FEV1 and smoking pack year exposure (Figure 4b). Hazard ratio for death in each cluster 231 
(compared to LCLR) was as follows: CVS (HR: 3.08; 95% CI 1.74-5.44; p<0.0001), Ex-TB 232 
(HR: 2.01; 95% CI 1.07-3.80; p<0.05), LCHR (HR: 1.59; 95% CI 0.89-2.85; p=ns) and diabetic 233 
(HR: 1.73; 95% CI 0.86-3.45; p=ns). Where respiratory-related causes of death are considered, 234 
the CVS, Ex-TB and LCHR clusters again illustrate the highest risk (Figure 4c). Smoking 235 
status, as in the derivation cohort, did not influence mortality (e-Figure 2c) or exacerbation 236 
severity (e-Figure 2d) in any cluster although the predominance of current smokers in the 237 
LCHR and ex-smokers in the LCLR clusters was reproduced (e-Table 4). Finally, to further 238 
verify the accuracy obtained in clustering the validation cohort using RDA Leave One Out 239 
Cross Validation, we generated a decision tree to classify Chinese individuals with COPD into 240 
one of our proposed five clusters (e-figure 4). This alternate classification methodology 241 
produced accuracy results of 72.4%, comparable to the RDA classification accuracies reported 242 
above. 243 
 244 
Following an unbiased semi-quantitative cytokine-array screen (evaluating 120 cytokines; data 245 
not shown), six cytokines (TNF-R1, TNF-R2, VEGF, PDGF-AA, PDGF-BB, PDGF-AB) were 246 
selected for confirmatory validation between clusters and compared to a group of non-COPD 247 
(healthy) controls (n=24) (e-Table 5). Independent of cluster, elevated TNF-R2 significantly 248 
associates with symptoms and severe exacerbations (e-Figure 5). Individual cytokines relating 249 
to each cluster were as follows: TNF-R2 and PDGF-AA in the CVS cluster; VEGF in the ex-250 
TB cluster and PDGF-AB and –BB in the LCHR cluster (Figure 5a; e-Table 6). Given observed 251 
differences for individual cytokines between clusters, we next assessed how cytokines 252 
‘interact’ within an inflammatory network and their respective complexity (Figure 5b). The 253 
CVS cluster (highest mortality) exhibits the most complex network with the highest number of 254 
positive cytokines and cytokine interactions. In line with the observed mortality in the 255 
derivation and validation cohorts, the ex-TB cluster followed by the LCHR, diabetic and LCLR 256 
respectively demonstrate gradients of decreasing cytokine network complexity (Figure 5b).  257 
 258 
We next assessed our ‘clusters’ in comparison to GOLD ABCD group and conventional GOLD 259 
staging. All patients were assigned to their respective GOLD grouping: A (17.0%; n=252), B 260 
(29.1%; n=430), C (12.9%; n=191) and D (41.0%; n=607) at study enrolment. All patients 261 
were also classified by conventional GOLD grade (FEV1 criteria) as follows: I (6.4%; n=95), 262 
II (34.5%; n=510), III (43.9%; n=650) and IV (15.2%; n=225) 14. Mortality at two-year follow 263 
up was assessed by cluster membership within each GOLD group (Figure 6) and GOLD grade 264 
(Figure 7). Across all GOLD groups and grades, the CVS and ex-TB clusters demonstrate 265 
highest mortality (Figure 6a, Figure 7). On univariate analysis, stratifying patients into GOLD 266 
groups, CVS and ex-TB clusters demonstrate highest mortality in GOLD A, C, and D, while 267 
CVS and LCHR in GOLD B (Figure 6a). CVS and ex-TB clusters demonstrate significantly 268 
higher mortality in multivariate logistic regression after adjustment for age, sex, BMI, FEV1, 269 
smoking pack year exposure, and GOLD group compared to LCLR cluster (Figure 6b). 270 
Adjusted odds ratio (ORs) for mortality in the CVS and ex-TB clusters (compared to LCLR 271 
group) were 2.98 (95% CI 1.88-4.73; p<0.001) and 1.852 (95% CI 1.17-2.92; p<0.01) 272 
respectively (Figure 6b). Similar trends were seen with adjusted hazard ratios (e-figure 6). 273 
FEV1 was not significant in independently predicting mortality in our logistic regression 274 
model. When the clusters were stratified by GOLD grade, significantly poorer two-year 275 
survival was observed in the CVS and ex-TB clusters irrespective of underlying (conventional) 276 
GOLD grade (Figure 7; p<0.05). Taken together, these data suggest that the CVS and ex-TB 277 
clusters perform poorly despite classification as ‘low risk’ by conventional GOLD group and 278 
staging necessitating early identification in Chinese populations.  279 
 280 
Discussion   281 
In this multi-center study across South-East Asia, we evaluated 1,480 Chinese patients with 282 
COPD and describe five validated ‘clusters’ with prognostic relevance. The two ‘highest-risk’ 283 
clusters were CVS and ex-TB which demonstrate high mortality risk. Our ‘cluster’ 284 
classification demonstrates differences in mortality outcome and associates with inflammatory 285 
signatures and cytokine network complexity.  286 
 287 
Cardiovascular disease and diabetes are well-recognized COPD co-morbidities and therefore 288 
identification of these ‘clusters’ was foreseen in view of existing evidence 17-22. In the Asian 289 
sub-continent however, rapid urbanization with improved socio-economic status has resulted 290 
in higher risks of cardiovascular consequences in COPD, with poorer prognosis, a finding 291 
consistent in our study 23-24. The highest mortality risk in our CVS ‘cluster’ warrants attention 292 
as prior Asian data suggests the under-treatment of COPD with co-existing cardiovascular 293 
disease 25. Several studies report increased mortality with concomitant diabetes in COPD 20, 26. 294 
Interestingly, however, in our work, the presence of diabetes illustrated better prognosis 295 
compared to the ‘high-risk’ CVS and ex-TB ‘clusters’ with some reports suggesting ethnic 296 
differences in diabetes-related mortality in South Asians and in particular Chinese 27. Two low 297 
co-morbidity clusters were identified that differed in mortality outcomes. The LCHR cluster 298 
contained high proportions of current smokers in contrast to the LCLR cluster with 299 
predominance of ex-smokers illustrating the benefits of smoking cessation to the natural course 300 
of COPD and its outcomes 28-29.  301 
 302 
Unlike some of the identified ‘clusters’, the ‘high-risk’ ex-TB cluster is novel and likely unique 303 
to Asians and other regions where TB is endemic. Patients in this ‘cluster’ completed treatment 304 
with clinical and microbiological resolution, however, recognized long-term sequelae of TB 305 
such as the high-risk of subsequent pulmonary obstruction persist 30-31. Post-TB related airways 306 
disease is commonly recognized in Asia however precise mechanisms remain unclear 31-33. 307 
Structural lung damage as a consequence of TB with pulmonary cavitation, bronchiectasis and 308 
endobronchial disease associates with increased risks of airflow obstruction, and, even with 309 
minimal change on chest radiography, risks of obstruction persist suggesting alternate 310 
mechanisms contributing to COPD development 34-35. One possibility is that pulmonary TB 311 
‘primes’ lung host defenses dysregulating responses to inhaled toxins, pathogens and cigarette 312 
smoke and increasing susceptibility to chronic lung disease despite infection clearance 35-36. 313 
Once chronic lung disease such as COPD has developed post-TB, host genetics and 314 
dysregulated immunity may play further roles in determining disease trajectory, progression 315 
and outcome illustrating why many patients with post-TB related chronic lung disease 316 
demonstrate aggressive clinical phenotypes with poorer outcome 35. A prior history of TB 317 
associates with morbidity and mortality in COPD, findings consistent with our work 37. Our 318 
clinical and inflammatory analyses further demonstrate complex networks and interactions in 319 
the ‘ex-TB’ cluster highlighting the possibility of ongoing systemic inflammation post-320 
infection (some of which may be attributed to higher exacerbation rates) contributing to their 321 
poorer outcome. Patient ethnicity influences TB-induced inflammation and therefore is of 322 
relevance in Chinese COPD38-39. 323 
 324 
Low-grade systemic inflammation is reported in COPD, however only a defined group of 325 
patients exhibit a persistent systemic inflammatory state with high mortality 40. Additionally, 326 
COPD can demonstrate Th-2 inflammatory responses with coexisting airway diseases such as 327 
asthma in asthma-COPD overlap syndrome (ACOS)41. Systemic inflammation in COPD is 328 
complex and involves interactions between multiple cytokines and their pathways 40. Using 329 
network analyses, we illustrate cytokine interactions occurring within each cluster. 330 
Interestingly, network complexity correlates with cluster mortality. Systemic inflammation is 331 
established in cardiovascular disease and when co-existing with COPD likely contributes to 332 
even greater levels in this cluster, where tumor necrosis factor (TNF) is identified. TNF 333 
promotes tissue inflammation, injury and reactive oxygen species, which in turn drives poorer 334 
prognostic outcomes. Vascular endothelial growth factor (VEGF), an angiogenesis promoter 335 
is described to have paradoxical roles in COPD: decreased in emphysematous and increased in 336 
bronchitis phenotypes. Interestingly, we detected significant VEGF levels in our ‘ex-TB’ 337 
cluster. An established body of evidence indicates that VEGF plays an essential role in TB 338 
pathogenesis enhancing granulomatous inflammation and its associated angiogenesis 42-43. 339 
VEGF increases in active TB, correlating with disease severity and while its levels are thought 340 
to improve post-treatment, its precise role in ‘ex-TB’ COPD is unclear 44-45. The role of 341 
platelets and their functional consequence in COPD is of interest 46-47. Platelet derived growth 342 
factor (PDGF)-related cytokines associate with the CVS and LCHR clusters and, have roles in 343 
cell signaling, lung development and cardiopulmonary disease 48. As a potent stimulant of 344 
smooth muscle proliferation, PDGF associates with small airway remodeling 49-50 and, while 345 
its role in COPD is uncertain, our findings suggest it to be an important systemic marker 346 
(perhaps associated with active smoking) for consideration in future studies in Chinese COPD.  347 
 348 
Our derived clusters demonstrate differences in mortality outcome despite conventional 349 
stratification by GOLD approaches used for COPD grouping and staging. This is considering 350 
our ‘highest-risk’ clusters: ‘CVS’ and ‘ex-TB’ which demonstrate high mortality and 351 
inflammatory complexity unrelated to underlying GOLD group or grade. Importantly, this 352 
indicates that some Chinese COPD patients within each GOLD group and grade (including that 353 
defined as low risk) do poorly and require attention. Furthermore, our defined clusters did not 354 
differ based on clinical COPD features alone (symptoms and lung function), with the exception 355 
of ‘ex-TB’ group with consistently low BMIs. A comprehensive tool incorporating 356 
cardiovascular and tuberculosis assessment may be of value to improve risk stratification in 357 
Chinese COPD populations. 358 
  359 
Here, we describe five clusters of Chinese COPD, at least three of which (cardiovascular, 360 
diabetic/metabolic and low-comorbidity) are broadly consistent with comparable studies in 361 
non-Chinese COPD populations 17-21. This work, unlike prior studies however did not identify 362 
any one cluster enriched for anxiety which overall demonstrates low prevalence in our dataset, 363 
potentially explained by employed diagnostic criteria. Similarly, we did not identify an 364 
underweight cluster, however, did observe lower BMIs in the ‘ex-TB’ group, a novel cluster 365 
with high mortality and relevant in any country with high TB prevalence. Understanding 366 
pathophysiological mechanisms in this cluster is an important avenue for future studies.    367 
 368 
Our work demonstrates clear strengths: it is the largest multi-center study to cluster Chinese 369 
COPD patients using strict diagnostic criteria including longitudinal follow up and assessment 370 
of separate validation and derivation cohorts 51. We employed robust statistical models to 371 
derive and validate clusters, adjusted for potential confounders and demonstrate high predictive 372 
accuracies. Despite strengths, our study does have limitations including being restricted to 373 
tertiary hospitals making data less generalizable to community based patients with milder 374 
disease. More than 90% of our COPD cohort was male, and while this is largely representative 375 
of the COPD population across Asia 7-8, it restricts applicability of our findings to female 376 
patients. It remains unclear and not addressed by this work whether Chinese females smoke 377 
less or have different susceptibilities to developing COPD. While all patients had chest 378 
radiography demonstrating no evidence of co-existing bronchiectasis, gold standard imaging 379 
of chest computed tomography (CT) was not available in all patients hence potential 380 
particularly TB-related sequelae may not have been identified. Furthermore, the precise timing 381 
of a tuberculosis diagnosis was not available in all patients; hence we cannot fully differentiate 382 
post-tuberculosis fixed airflow limitation from COPD in appropriate patients.  While we 383 
present a simplified CART (decision tree) model to classify patients into our described five 384 
clusters, its accuracy was significantly lower than that from our RDA model hence further 385 
research is clearly necessary before simplified models for patient classification can be routinely 386 
implemented into clinical practice. For inflammatory work, we selected a restricted final panel 387 
of six cytokines based on strict semi-quantitative screening criteria (at least 2.5-fold differences 388 
between clusters). If we decreased fold difference cut-offs, we may have identified more 389 
cytokines of relevance to our clusters. All clinical data used for derivation of clusters was 390 
collated at time of recruitment and therefore stability of the clusters or patient membership 391 
within them over time was not examined and is an interesting area for follow up. Validation of 392 
our clusters in Chinese COPD patients outside Asia (including BODE assessment) and among 393 
other ethnic populations (e.g. Malays, Indians) within Asia should be pursued. Despite 394 
demonstrating the robustness of our clustering algorithm, clustering in COPD does have its 395 
limitations and has been previously shown to result in marked heterogeneity52. When 396 
comparing our cluster mortality with classic COPD mortality prediction models such as the 397 
ADO index53, we found no significant differences. Future work should assess the additive value 398 
of our derived clusters in Chinese COPD using classic COPD mortality prediction models 399 
including BODE. 400 
 401 
We describe, for the first time, validated clusters of Chinese COPD patients including two 402 
‘high-risk’ patient groups. TB and COPD while associated, are independent key public health 403 
concerns demonstrating an unmet need by our work. Overall, our findings improve risk 404 
stratification in Chinese COPD patients identifying those at ‘highest risk’ requiring close 405 
monitoring and appropriate intervention.  406 
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Figure legends 618 
Figure 1: Unsupervised clustering (of the derivation cohort) reveals five clinically relevant 619 
patient clusters of ethnic-Chinese patients with chronic obstructive pulmonary disease (COPD) 620 
demonstrating variable prognostic outcome. Dendrogram illustrating the five derived COPD 621 
clusters using non-metric multidimensional scaling followed by hierarchical clustering. 622 
Different clusters are represented by colours: Ex-tuberculosis (green), diabetic (blue), low co-623 
morbidity: low-risk (violet red), low co-morbidity: high-risk (yellow) and cardiovascular 624 
(pink). Ex-TB: ex-tuberculosis, LCLR: low co-morbidity: low-risk. LCHR: low co-morbidity: 625 
high-risk, CVS: cardiovascular 626 
 627 
Figure 2: Kaplan-Meier curve (a) demonstrating survival differences between clusters for two-628 
year all-cause mortality: worst prognosis in the cardiovascular and ex-tuberculosis (TB) 629 
clusters which (b) remains significant after adjustment for age, sex, BMI, FEV1 and smoking 630 
pack year exposure illustrated as cox regression survival curves. (c) Cumulative incidence 631 
curves for each of the five derived COPD clusters for respiratory causes of death: greatest 632 
incidence of respiratory cause of death observed in the cardiovascular, ex-tuberculosis and low 633 
co-morbidity: high-risk clusters. Different clusters are represented by colours: Ex-tuberculosis 634 
(green), diabetic (blue), low co-morbidity: low-risk (violet red), low co-morbidity: high-risk 635 
(yellow) and cardiovascular (pink). Ex-TB: ex-tuberculosis, LCLR: low co-morbidity: low-636 
risk. LCHR: low co-morbidity: high-risk, CVS: cardiovascular 637 
 638 
Figure 3: Validation cohort (V; n=569) of patients with Chronic Obstructive Pulmonary 639 
Disease (COPD) of Chinese ethnicity illustrates comparable co-morbidity profiles by cluster 640 
when compared to the Derivation (D; n=911) cohort. Bubble size corresponds to the percentage 641 
of patients demonstrating each comorbidity within their respective cohort and bubble colour 642 
represents cluster membership:  Ex-tuberculosis (green), diabetic (blue), low co-morbidity: 643 
low-risk (violet red), low co-morbidity: high-risk (yellow) and cardiovascular (pink). PUD: 644 
peptic ulcer disease, pTB: history of prior pulmonary tuberculosis, PAD: peripheral arterial 645 
disease, Other Ca: all other malignancies excluding lung, esophageal, pancreatic or breast 646 
carcinoma, DM: diabetes mellitus, CVA: cerebrovascular disease, CKD: chronic kidney 647 
disease, CHF: congestive heart failure, CAD: coronary artery disease, Ca: lung, esophageal, 648 
pancreatic or breast carcinoma, AF: atrial fibrillation. 649 
 650 
Figure 4: Survival outcomes between the identified clusters in the validation cohort for two-651 
year all-cause mortality (as demonstrated independently in the Derivation (D; n=911) cohort; 652 
see Figure 2): (a) Kaplan-Meier curves demonstrating worst prognosis in the cardiovascular 653 
and ex-tuberculosis clusters which (b) remains significant after adjustment for age, sex, BMI, 654 
FEV1 and smoking pack year exposure illustrated as cox regression survival curves. (c) 655 
Comparable cumulative incidence curves for each of the five derived COPD clusters (as 656 
demonstrated independently in the Derivation (D; n=911) cohort; see Figure 2) for respiratory 657 
causes of death: greatest incidence of respiratory cause of death observed in the cardiovascular, 658 
ex-tuberculosis and low co-morbidity: high-risk clusters. Different clusters are represented by 659 
color: Ex-tuberculosis (green), diabetic (blue), low co-morbidity: low-risk (violet red), low co-660 
morbidity: high-risk (yellow) and cardiovascular (pink). Ex-TB: ex-tuberculosis, LCLR: low 661 
co-morbidity: low-risk, LCHR: low co-morbidity: high-risk, CVS: cardiovascular 662 
 663 
Figure 5: The five derived COPD clusters of Chinese ethnicity illustrate inflammatory 664 
signatures that associate with all cause and respiratory-related mortality. (a) Radar plot 665 
illustrating variation in systemic cytokine profile between each of the five derived COPD 666 
clusters. The median normalized score for each selected cytokine (in the final assessed panel) 667 
is plotted on the radar chart for comparison between clusters. Each dot represents the median 668 
normalized value of the cytokine and the colour indicates the specific cluster: Ex-tuberculosis 669 
(green), diabetic (blue), low co-morbidity: low-risk (violet red), low co-morbidity: high-risk 670 
(yellow) and cardiovascular (pink). TNF-R1: tumor necrosis factor receptor 1, TNF-R2: tumor 671 
necrosis factor receptor 2, VEGF: vascular endothelial growth factor, PDGF: platelet derived 672 
growth factor. *p ≤ 0.05, #p <0.1. (b) Network plots demonstrating inflammatory grids detected 673 
within each cluster. Increased cytokine interaction and a greater number of positive cytokines 674 
are detectable in the cardiovascular, ex-tuberculosis and low co-morbidity: high-risk clusters 675 
compared to the diabetic and low co-morbidity: low-risk clusters (indicated by ‘greater than’ 676 
(>) symbols). Each circle (node) represents a cytokine from the final assessed panel: circle size 677 
corresponds to percentage of patients within that cluster demonstrating a positive value. Lines 678 
connecting two nodes indicate positive detection of both cytokines and line thickness illustrates 679 
the proportion of patients with a positive result for both cytokines. Node color corresponds to 680 
the respective clinical cluster: Ex-tuberculosis (green), diabetic (blue), low co-morbidity: low-681 
risk (violet red), low co-morbidity: high-risk (yellow) and cardiovascular (pink).  682 
 683 
Figure 6: Cardiovascular and ex-tuberculosis clusters illustrate highest two-year mortality (a) 684 
Tree map illustrating cluster related mortality within each GOLD group [A, B, C and D]. 685 
Rectangles represent the proportion of deceased patients within each group, presented as 686 
percentages. Rectangle colour indicates cluster membership: Ex-tuberculosis (green), diabetic 687 
(blue), low co-morbidity: low-risk (violet red), low co-morbidity: high-risk (yellow) and 688 
cardiovascular (pink). (b) The mortality differences remain significant after adjustment for age, 689 
sex, BMI, smoking pack year exposure, lung function (by FEV1) and GOLD group illustrated 690 
by forest plot using multivariate logistic regression. The dot represents the odds ratio with 691 
colour indicating significance levels: red (p <0.05), grey (p>0.05; ns). Error bar indicates the 692 
95% confidence interval (CI). FEV1: forced expiratory volume in the 1st second. Ex-TB: ex-693 
tuberculosis, LCLR: low co-morbidity: low-risk, LCHR: low co-morbidity: high-risk, CVS: 694 
cardiovascular. 695 
 696 
Figure 7: Cardiovascular and ex-tuberculosis clusters demonstrate poorest two-year survival 697 
irrespective of underlying COPD grade. Kaplan-Meir curves illustrating two-year mortality of 698 
each cluster by conventional COPD staging (defined by FEV1). *p ≤ 0.05, **p=0.001 by log-699 
rank test. Different clusters are represented by colours: Ex-tuberculosis (green), diabetic (blue), 700 
low co-morbidity: low-risk (violet red), low co-morbidity: high-risk (yellow) and 701 
cardiovascular (pink). Ex-TB: ex-tuberculosis, LCLR: low co-morbidity: low-risk. LCHR: low 702 
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e-Appendix 1: Ethical approval 733 
The institutional ethics review boards of all participating hospitals approved the study as 734 
follows: DSRB 2012/01110, CIRB 2018/2186 (2013/184/C), CIRB 2016/2715, CIRB 735 
2017/3010, CIRB 2017/2933 (all mutually recognized by DSRB, Singapore), NNMR-13-736 
313-15138, UMMC 2018725-6524 (Malaysia), CREC 2011.146, CREC 2015.164 and CREC 737 
2018.042 (Hong Kong). Non-COPD (healthy) patient recruitment was approved by the NTU 738 
institutional ethics review board under IRB-2017-12-010. 739 
 740 
e-Appendix 2: Additional methods 741 
Clinical data collation: Clinical data was obtained for all subjects at recruitment and included 742 
demographics, smoking history (including pack year exposure where relevant), number of 743 
acute exacerbations requiring hospitalization in the previous year (from time of recruitment), 744 
sputum (culture positive) microbiology, COPD assessment test (CAT) scores and, co-745 
morbidities by the COPD specific co-morbidity test (COTE) 1. Comorbidities recorded 746 
through COTE include: anxiety, atrial fibrillation/flutter, coronary artery disease, congestive 747 
heart failure, diabetes mellitus, liver cirrhosis, malignancy, gastric or duodenal ulcers (peptic 748 
ulcer disease). Additional comorbidities noted by the recruiting clinician at study entry and 749 
verified through patient medical records were also documented. These include chronic kidney 750 
disease, cerebrovascular disease/stroke, peripheral arterial disease, asthma, prior documented 751 
pulmonary tuberculosis, chronic respiratory failure, pulmonary hypertension and 752 
osteoporosis. Co-morbidities were assessed in all patients at enrolment and definitions of 753 
each comorbidity are provided below. Sputum microbiology was obtained through 754 
spontaneous expectorated and representative sputum (<10 squamous epithelial cells and >25 755 
leucocytes per low-power microscopic field 2-3. Two-year mortality (as documented on the 756 
death certification) and number of exacerbations including hospitalizations (for COPD 757 
exacerbations) in the subsequent year following recruitment was prospectively recorded. A 758 
COPD exacerbation was defined as a sudden deterioration of respiratory symptoms requiring 759 
additional therapy (steroids and/or antibiotics) 4. Severe exacerbators were defined as the 760 
occurrence of one or more exacerbations requiring hospitalization 4. Respiratory cause of 761 
death was defined as death secondary to pneumonia, chronic obstructive pulmonary disease 762 
or respiratory failure.  763 
 764 
Co-morbidity definitions: Anxiety was diagnosed based on DSM-V criteria 5. Atrial 765 
fibrillation/flutter was defined by the presence of electrocardiogram criteria including 766 
absence of P waves, irregular R-R intervals and atrial activity 6. Congestive heart failure was 767 
diagnosed by echocardiography 7. Coronary artery disease was defined based on functional 768 
testing, radiological imaging and/or coronary angiography 8. Diabetes mellitus was defined as 769 
the presence of either fasting blood glucose levels of ≥7.0 mmol/l, blood glucose levels of 770 
≥11.1 mmol/l two-hour post oral glucose tolerance test, random blood glucose level ≥11.1 771 
mmol/l with hyperglycemia symptoms, or HbA1c ≥6.5% 9. Liver cirrhosis was defined by the 772 
presence of clinical, biochemical and radiological features of liver failure with or without 773 
liver biopsy 10. Respective malignancies were diagnosed by radiological imaging and/or 774 
histological confirmation. Peptic ulcer disease was diagnosed by endoscopy 11. Chronic 775 
kidney disease was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min, 776 
according to the National Kidney Foundation Kidney Disease Outcome Quality Initiative 777 
guidelines 12. Cerebrovascular disease/stroke was defined as a previously documented central 778 
nervous system infarction or hemorrhage 13. Peripheral arterial disease was defined as ankle 779 
brachial index of ≤0.9 14. Asthma was defined according to the Global Initiative of Asthma 780 
(GINA) guidelines based on past history, symptoms and the presence of variable expiratory 781 
airflow limitation 15. Previous pulmonary tuberculosis was defined as a prior history of 782 
documented tuberculosis with positive sputum analysis for mycobacteria tuberculosis 783 
including positive acid-fast bacilli smear, culture or nucleic acid amplification, radiological 784 
features (on chest radiography or computed tomography) and/or prior pharmacological 785 
treatment for pulmonary tuberculosis 5, 16-17. Chronic respiratory failure was defined as either 786 
requiring long-term oxygen therapy or non-invasive ventilation with PCO2 > 52mmHg 4, 18. 787 
Pulmonary hypertension was defined as an increased mean pulmonary arterial pressure (PAP) 788 
≥25mmHg at rest assessed by transthoracic echocardiography and/or right heart 789 
catheterization 19. Osteoporosis was defined by radiological imaging 20. Comorbidities were 790 
obtained from patient histories and verified through medical records, including medication 791 
lists and therapies received for specific disease states. Where data was unavailable or could 792 
not be verified for any one particular co-morbidity, the patient was classified as not 793 
demonstrating that respective co-morbidity.  794 
 795 
Non-COPD (healthy) patient recruitment: Non-COPD subjects were recruited from 796 
community volunteers who participated in an exercise program conducted at Nanyang 797 
Technological University, Singapore aged >60 years with a measured FEV1/FVC>0.7 with 798 
normal FEV1 (≥80% predicted).  799 
 800 
Venous blood sampling and processing: Venous blood samples were collected from non-801 
COPD (healthy) controls (n=24) and COPD patients (n=336) from Singapore (n=74); 802 
Malaysia (n=49) and Hong Kong (n=213). Samples were immediately transferred to a local 803 
laboratory and centrifuged at 1300g for 10 minutes at 18°C to isolate plasma which was then 804 
maintained at -80qC until inflammatory assessment. All assessments were performed in 805 
Singapore and temperature-controlled shipments permitted safe transfer of specimens 806 
between sites.  807 
 808 
Cytokine (Inflammatory) assessment: To determine a ‘cytokine panel’ of relevance to 809 
differentiate the detected COPD ‘clusters’, we first screened for the presence of 120 different 810 
cytokines using the Raybiotech human cytokine array C2000 kit according to the 811 
manufacturer’s instructions. A pooled plasma sample from each respective detected cluster 812 
(randomly selected) was used for screening which contained n=20 separate patients plasma 813 
(pooled) where patients were recruited from all different participating sites. Briefly, diluted 814 
plasma (1:8) was incubated with cytokine membrane arrays containing antibodies at 4˚C 815 
overnight according to the manufacturer’s instructions. Following washing with appropriate 816 
buffers and incubation with secondary antibodies, detection was performed using horseradish 817 
peroxidase labeled streptavidin. Raw data were analyzed with the Raybio@ analysis software 818 
tool and six cytokines (PDGF-AA, PDGF-AB, PDGF-BB, VEGF-A, TNFR1, TNFR2) 819 
selected (based on a minimum of at least a 2.5-fold difference from at least one other cluster) 820 
for quantitative confirmatory validation assays. For conformation and protein quantification, 821 
a customized ProcartaPlex immunoassay panel (Thermo Fisher Scientific) consisting of 822 
PDGF-BB, VEGF-A, TNF-R1 and TNF-R2 was used in combination with human PDGF-AB 823 
(EHPDGFAB) and PDGF-AA (EHPDGFAA) ELISAs (Thermo Fisher Scientific) and 824 
experiments performed as per manufacturer’s instructions. Twenty-five microliters of plasma 825 
(in duplicate) was used for ProcartaPlex panel and the plates read using Bio-Plex-200 system 826 
(Bio-Rad). The concentration of each cytokine was generated with standard curves using Bio-827 
Plex manager software 6.1. The proportion of patients in each detected COPD cluster used 828 
for inflammatory assessments was comparable to that observed in both the derivation and 829 
validation cohorts as follows: Ex-tuberculosis (17%), diabetic (19%), low co-morbidity: low-830 





e-Appendix 3: Statistical analysis 836 
Statistical analysis was performed using RStudio (Version 1.1.453, Integrated Development 837 
for R. RStudio, Inc., Boston, MA) and Python (Version 2.7). All continuous variables were 838 
not normally distributed; hence all continuous data is presented as medians (with interquartile 839 
ranges). To compare differences between groups, the Kruskal-Wallis and Dunn test (with 840 
Benjamini-Hochberg correction for false discovery rate) were employed for continuous 841 
variables and Fisher exact or Chi-squared test performed for categorical data as appropriate. 842 
Significance level is defined as p-values <0.05(*); <0.01(**) and <0.001(***). 843 
 844 
Clustering analysis: Clinical variables, including numerical and categorical data were used 845 
for patient clustering. These include age, body mass index (BMI), lung function, CAT scores, 846 
sex, smoking status (and smoking pack year exposure where relevant), co-morbidities and 847 
sputum microbiology. For data transformation, a Gower dissimilarity matrix was calculated 848 
using the R function ‘daisy’ from the “Cluster package”. ‘Sammon’, a non-metric 849 
multidimensional scaling (NMDS) algorithm was implemented on this Gower dissimilarity 850 
matrix using an appropriate value of ‘k’ as determined by a Screen plot. Embedding all 851 
patients into a Euclidean Space of k=8, Ward's minimum-variance unsupervised hierarchical 852 
clustering method was applied on this transformed/embedded dataset using an agglomerative 853 
approach with the ‘hclust’ function of the “Cluster” Package. The optimal number of 854 
derivation clusters was determined with R package “Nbclust”. Cluster stabilities were 855 
investigated via computing the Jaccard similarities index, with bootstrapping over 100 856 
iterations using the R package “fpc”. The mean Jaccard similarities index was 0.79 857 
suggesting stability of the identified clusters. Assignment of cluster membership of the 858 
validation cohort was carried out using a trained Regularised Discriminant Analysis (RDA) 859 
model. The RDA model with a uniform prior was trained on the data-transformed derivation 860 
cohort with cluster membership as class labels using “klaR” package in R. Model parameters, 861 
lambda and gamma were tuned to an optimal value. To account for the randomness, a nested 862 
approach was implemented over 100 iterations with random seeds. At each iteration, optimal 863 
model parameters were determined numerically by minimizing the estimated 864 
misclassification rate, which is estimated by dividing the data into 70% training and 30% 865 
testing over 100 bootstrap iterations. In order to find the high-density region (median) of the 866 
optimal model parameters, a kernel density estimation (KDE) of these parameters was 867 
generated using the “seaborn” library in python. The median optimal lambda and gamma, 868 
chosen from the darkest region of KDE density plot corresponded to gamma of 0.012 and 869 
lambda of 0.130 (e-Figure 3). The leave one out cross validation (LOOCV) accuracy of the 870 
RDA model with optimal parameters was found to be 97.9%. To validate the derived cluster 871 
groups, the validation cohort was data-transformed and the trained RDA model, on 70% of 872 
the derivation cohort (training dataset) was used to predict the class membership probabilities 873 
of the patients from the validation cohort (e-Table 3). Class labels were assigned based on the 874 
maximum probability of a patient being in that class. 875 
 876 
Decision tree: CART (Classification and Regression trees), a supervised classification 877 
algorithm was implemented using sklearn21 in python 2.7, to derive a simplistic model to 878 
predict cluster membership using baseline clinical data from the derivation cohort. This 879 
decision tree was pruned to make the model simple for clinical application. Using the 880 
validation cohort, the accuracy of the decision tree was 72%.  881 
 882 
Survival analysis: Survival analysis was performed using R packages “survival” and 883 
“survminer”. All-cause mortality was assessed and compared with Kaplan-Meier curves, log-884 
rank test and cox proportional hazards regression model adjusted for age, sex, BMI, forced 885 
expiratory volume in the 1st second (FEV1) and smoking pack year exposure 22. Respiratory 886 
causes of death were further compared with non-respiratory causes with competing risk 887 
analysis using the R package “cr17”. Sankey plots were used to visualize the differences 888 
between smoking status in each cluster with mortality and severe exacerbation, using 889 
“ggalluvial” package in R. Multivariate logistic regression adjusted for age, sex, BMI, FEV1, 890 
smoking pack year exposure, and GOLD group was performed using ‘glm’ function in R, a 891 
Hosmer and Lemeshow test for the model was assessed using “generalhoslem” package in R. 892 
 893 
Inflammatory analyses: Cytokine data was corrected for batch variation with the R 894 
“MdimNormn” package 23. The median values were normalized to percentage differences 895 
between the clusters and plotted on a radar chart using the “ggiraphExtra” package in R. 896 
Network diagrams of the six cytokines for each respective clinical cluster was generated 897 
using “tidygraph” and “ggraph” package in R. Nodes represent the percentage of patients 898 
with positive cytokines, the edge (line) illustrates cytokine connectivity and edge attributes 899 
(line thickness) represents the proportion of patients demonstrating positive cytokine 900 
connections. An elevated cytokine concentration (i.e. the ‘cut off’) was defined as a value 901 
above the detected 95th percentile of non-COPD subjects in accordance with prior published 902 











1. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. 914 
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. 915 
Am J Respir Crit Care Med. 2012;186(2):155-61. 916 
2. Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated 917 
sputum. Mayo Clin Proc. 1975;50(6):339-44. 918 
3. Van Scoy RE. Bacterial sputum cultures. A clinician's viewpoint. Mayo Clin Proc. 919 
1977;52(1):39-41. 920 
4. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, 921 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. (http://goldcopd.org/); 922 
2018. 923 
5. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This 924 
official statement of the American Thoracic Society and the Centers for Disease Control and 925 
Prevention was adopted by the ATS Board of Directors, July 1999. This statement was 926 
endorsed by the Council of the Infectious Disease Society of America, September 1999. Am 927 
J Respir Crit Care Med. 2000;161(4 Pt 1):1376-95. 928 
6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC 929 
Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. 930 
European journal of cardio-thoracic surgery : official journal of the European Association for 931 
Cardio-thoracic Surgery. 2016;50(5):e1-e88. 932 
7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 933 
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task 934 
Force for the diagnosis and treatment of acute and chronic heart failure of the European 935 
Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure 936 
Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. 937 
8. Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 938 
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on 939 
the management of stable coronary artery disease of the European Society of Cardiology. Eur 940 
Heart J. 2013;34(38):2949-3003. 941 
9. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of 942 
Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13-S27. 943 
10. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51. 944 
11. Committee ASoP, Banerjee S, Cash BD, Dominitz JA, Baron TH, Anderson MA, et 945 
al. The role of endoscopy in the management of patients with peptic ulcer disease. 946 
Gastrointest Endosc. 2010;71(4):663-8. 947 
12. Kovacic B, Sehl C, Wilker B, Kamler M, Gulbins E, Becker KA. Glucosylceramide 948 
Critically Contributes to the Host Defense of Cystic Fibrosis Lungs. Cell Physiol Biochem. 949 
2017;41(3):1208-18. 950 
13. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An 951 
updated definition of stroke for the 21st century: a statement for healthcare professionals 952 
from the American Heart Association/American Stroke Association. Stroke. 953 
2013;44(7):2064-89. 954 
14. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman 955 
DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity 956 
Peripheral Artery Disease: Executive Summary: A Report of the American College of 957 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 958 
Circulation. 2017;135(12):e686-e725. 959 
15. Global Initiative for Asthma. Global Management and Prevention 2018. 960 
http://www.ginasthma.org. 961 
16. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. 962 
Official American Thoracic Society/Infectious Diseases Society of America/Centers for 963 
Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in 964 
Adults and Children. Clin Infect Dis. 2017;64(2):111-5. 965 
17. Jung KH, Kim SJ, Shin C, Kim JH. The considerable, often neglected, impact of 966 
pulmonary tuberculosis on the prevalence of COPD. Am J Respir Crit Care Med. 967 
2008;178(4):431; author reply 2-3. 968 
18. Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, et al. Effect 969 
of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on 970 
Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical 971 
Trial. JAMA. 2017;317(21):2177-86. 972 
19. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS 973 
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force 974 
for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of 975 
Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association 976 
for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart 977 
and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. 978 
20. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical 979 
guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. 980 
21. Fabian Pedregosa GV, Alexandre Gramfort, Vincent Michel, Bertrand Thirion, 981 
Olivier Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, Vincent Dubourg, Jake 982 
Vanderplas, Alexandre Passos, David Cournapeau, Matthieu Brucher, Matthieu Perrot, 983 
Édouard Duchesnay. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 984 
2011(12):2825-30. 985 
22. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, et al. Comorbidity, 986 
systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 987 
2013;107(9):1376-84. 988 
23. Mac Aogain M, Tiew PY, Lim AYH, Low TB, Tan GL, Hassan T, et al. Distinct 989 
'Immuno-Allertypes' of Disease and High Frequencies of Sensitisation in Non-Cystic-990 
Fibrosis Bronchiectasis. Am J Respir Crit Care Med. 2018. 991 
24. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. 992 
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel 993 
phenotype. PLoS One. 2012;7(5):e37483. 994 
995 
SUPPLEMENTARY TABLES AND LEGENDS 996 
 997 
e-Table 1: Demographic table showing baseline characteristics of the derivation and 998 










Age (years), Median (IQR) 74 (68-79) 74 (68-79) 74 (69-81) 
Country, n (%)    
Singapore  630 (42.6) 406 (44.5) 224 (39.4) 
Hong Kong 720 (48.6) 425 (46.7) 292 (51.8) 
Malaysia 130 (8.8) 80 (8.8) 50 (8.8) 
Sex (Male), n(%) 1396 (94.6) 868 (95.3) 531 (93.3) 
Smoking status, n(%)    
Current smoker 690 (46.6) 547 (60.0) 143 (25.1) 
Ex- smoker 773 (52.2) 362 (39.8) 411 (72.2) 
Non-smoker 17 (1.2) 2 (0.2) 15 (2.7) 



























Total number of exacerbations 
per year, 
Median (IQR) 
1 (0-2) 1 (0-3) 1 (0-2) 
Hospitalized exacerbations, 
Median (IQR) 
0 (0-2) 1 (0-2) 0 (0-1) 
COTE Index, Median (IQR) 0 (0-2) 0 (0-2) 1 (0-2) 
 1000 
Data are presented as number of patients (n) (with percentage; %) or median (and 1001 
interquartile range; IQR). BMI: body mass index; FEV1: forced expiratory volume in the 1st 1002 




















e-Table 2: Baseline characteristics of the five derived chronic obstructive pulmonary disease 1023 
(COPD) clusters (from the derivation cohort). 1024 

















n (%) 911 156 (17) 109 (12) 192 (21) 339 (37) 115 (13)  










53 (34.0) 54 (49.5) 50 (26.1) 234 (69.0) 34 (29.5)  
















































































































































Total number of 
exacerbations per 






1 (0-2) 1 (0-2) 1 (0-2) 0 (0-2) 0 (0-2) 1 (0-3) 0.003 
COTE Index, 
Median (IQR) 


















43 (4.7) 9 (5.8) 3 (2.8) 4 (2.1) 22 (6.5) 5 (4.3) 0.154 
S.pneumoniae, n 
(%) 
33 (3.6) 6 (3.8) 5 (4.6) 8 (4.2) 11 (3.2) 3 (2.6) 0.917 
M.catarrhalis, n 
(%) 
24 (2.6) 4 (2.6) 3 (2.8) 2 (1.0) 11 (3.2) 4 (3.5) 0.606 
K.pneumoniae, n 
(%) 
13 (1.4) 1 (0.6) 6 (5.5) 1 (0.5) 3 (0.9) 2 (1.7) 0.004 
Acinetobacter 
spp., n (%) 
10 (1.1) 2 (1.3) 1 (0.9) 0 (0.0) 6 (1.8) 1 (0.9) 0.451 
Fungi, n (%) 9 (1.0) 3 (1.9) 1 (0.9) 0 (0.0) 5 (1.5) 0 (0.0) 0.259 
Other bacteria, n 
(%) 
22 (2.4) 1 (0.6) 1 (0.9) 0 (0.0) 15 (4.4) 5 (4.3) 0.004 
 1025 
Data are presented as number of patients (n) (with percentage; %) or median (and 1026 
interquartile range; IQR). FEV1: forced expiratory volume in the 1st second; FVC: forced 1027 
vital capacity, COPD: chronic obstructive pulmonary disease; COTE: COPD specific co-1028 
morbidity test. H. influenzae: Haemophilus influenzae, P.aeruginosa: Pseudomonas 1029 
aeruginosa, S.pneumoniae: Streptococcus pneumoniae, M.catarrhalis: Moraxella 1030 




e-Table 3: Confusion matrix showing the predicted and actual cluster identities (expressed as 1035 
number of patients, n and percentage; %) generated from the derivation cohort (n= 911) using 1036 
Regularised Discriminant Analysis (RDA). We note that the Leave One Out Cross Validation 1037 
(LOOCV) accuracy of the RDA model with optimal parameters was 97.9% (confusion matrix 1038 
not shown),  illustrative of a robust model. This model was used to predict cluster identity for 1039 










































0 (0.0%) 0 (0.0%) 
191 
(99.5%) 





0 (0.0%) 7 (2.0%) 2 (0.6%) 
324 
(95.6%) 


















e-Table 4: Baseline characteristics of the five derived chronic obstructive pulmonary disease 1053 
(COPD) clusters (from the validation cohort). 1054 









































45 (51.1) 99 (51.3) 56 (49.1)  




















































































































































0 (0-1) 0 (0-1) 0 (0-1) 1 (0-2) 0 (0-1) 0 (0-2) 0.314 
COTE Index,  
Median (IQR) 




89 (15.6) 30 (29.4) 8 (11.1) 7 (8.0) 28 (14.5) 16 (14.0) <0.001 
H.influenzae, n 
(%) 
30 (5.3) 6 (5.9) 1 (1.4) 3 (3.4) 14 (7.3) 6 (5.3) 0.377 
P.aeruginosa, n 
(%) 
19 (3.3) 9 (8.8) 2 (2.8) 0 (0.0) 4 (2.1) 4 (3.5) 0.012 
S.pneumoniae, n 
(%) 
9 (1.6) 3 (2.9) 0 (0.0) 1 (1.1) 1 (0.5) 4 (3.5) 0.135 
M.catarrhalis, n 
(%) 
13 (2.3) 4 (3.9) 3 (4.2) 1 (1.1) 4 (2.1) 1 (0.9) 0.423 
K.pneumoniae, n 
(%) 




6 (1.1) 1 (1.0) 0 (0.0) 1 (1.1) 3 (1.6) 1 (0.9) 0.970 
Fungi, n (%) 3 (0.5) 3 (3.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.011 
Other bacteria, n 
(%) 
9 (1.6) 3 (3.0) 1 (1.4) 0 (0.0) 4 (2.1) 1 (0.9) 0.535 
 1055 
Data are presented as number of patients (n) (with percentage; %) or median (and 1056 
interquartile range; IQR). FEV1: forced expiratory volume in the 1st second; FVC: forced 1057 
vital capacity, COPD: chronic obstructive pulmonary disease; COTE: COPD specific co-1058 
morbidity test. H. influenzae: Haemophilus influenzae, P.aeruginosa: Pseudomonas 1059 
aeruginosa, S.pneumoniae: Streptococcus pneumoniae, M.catarrhalis: Moraxella 1060 
catarrhalis, K.pneumoniae: Klebsiella pneumoniae. 1061 
 1062 
 1063 
e-Table 5: Demographic table showing baseline characteristics and inflammatory (cytokine) 1064 










Age (years), Median (IQR) 73 (67-79) 64 (59-68) 74 (67-79) <0.0001 
Sex (Male), n (%) 332 (92.2) 9 (38.0) 323 (96.1) <0.001 
Current smoker, n (%) 221 (61.4) 3 (12.5) 218 (64.9) <0.0001 
Smoking pack years, Median 
(IQR) 
50 (40-68) 40 (37-47) 50 (40-70) 0.364 
























COPD assessment test (CAT),  
Median (IQR) 
14 (9-20) NA 14 (9-20) NA 
Hospitalized exacerbations, 
Median (IQR) 
0 (0-2) NA 0 (0-2) NA 
COTE Index, Median (IQR) 1 (0-2) NA 1 (0-2) NA 




































PDGF-AA (pg/ml), Median 
(IQR) 
1.9 x105 
(6.3 x104 - 
4.8x105) 
2.2 x105 
















Data are presented as number of patients (n) (with percentage; %) or median (and 1067 
interquartile range; IQR). FEV1: forced expiratory volume in the 1st second; FVC: forced 1068 
vital capacity, COPD: chronic obstructive pulmonary disease; COTE: COPD specific co-1069 
morbidity test; TNF-R1: tumor necrosis factor receptor 1; TNF-R2: tumor necrosis factor 1070 
receptor 2; VEGF: vascular endothelial growth factor; PDGF: platelet derived growth factor. 1071 
e-Table 6: : Demographic table showing baseline characteristics and inflammatory 1072 




















n, (%) 336 59 (17) 63 (19) 33 (10) 131 (39) 50 (15)  
Centre, n (%)        
Singapore 74 (22) 12 (20) 7 (11) 4 (12) 33 (25) 18 (36) 0.035 
Hong Kong 213 (63) 35(60) 47 (75) 23 (70) 84 (64) 24 (48)  
Malaysia 49 (15) 12 (20) 9 (14) 6 (18) 14 (11) 8 (16)  














Sex (Male), n (%) 
323 
(96.1) 
56 (94.9) 59 (93.7) 32 (97.0) 128 (97.7) 48 (96.0) 0.633 











































































































Total number of 
exacerbations per 
year, Median (IQR) 




0 (0-2) 0 (0-2) 0 (0-1) 0 (0-1) 0 (0-2) 1 (0-3) 0.724 
COTE Index, 
Median (IQR) 
1 (0-2) 0 (0-2) 2 (2-3) 0 (0-1) 0 (0-0) 2 (1-4) <0.001 

































































































































Data are presented as number of patients (n) (with percentage; %) or median (and 1075 
interquartile range; IQR). FEV1: forced expiratory volume in the 1st second; FVC: forced 1076 
vital capacity, COPD: chronic obstructive pulmonary disease; COTE: COPD specific co-1077 
morbidity test; TNF-R1: tumor necrosis factor receptor 1; TNF-R2: tumor necrosis factor 1078 





  1084 
e-Figure 1: Derivation (D; n=911) and validation cohorts (V; n=569) of patients with 1085 
Chronic Obstructive Pulmonary Disease (COPD) of Chinese ethnicity illustrate comparable 1086 
comorbidity and sputum microbiology profiles. Bubble charts illustrating the proportion of 1087 
patients demonstrating an established indicated comorbidity between (a) the overall cohorts, 1088 
(b) based on country of origin and (c) sputum microbiology. Bubble size corresponds to the 1089 
percentage of patients demonstrating each comorbidity and detectable microorganisms by 1090 
sputum culture within their respective cohort and bubble colour represents the country of 1091 
patient origin: light green: derivation (overall), dark green: validation (overall), red: 1092 
Singapore, blue: Hong Kong, purple: Malaysia. PUD: peptic ulcer disease, pTB: history of 1093 
prior pulmonary tuberculosis, PAD: peripheral arterial disease, Other Ca: all other 1094 
malignancies excluding lung, esophageal, pancreatic or breast carcinoma, DM: diabetes 1095 
mellitus, CVA: cerebrovascular disease, CKD: chronic kidney disease, CHF: congestive heart 1096 
failure, CAD: coronary artery disease, Ca: lung, esophageal, pancreatic or breast carcinoma, 1097 
AF: atrial fibrillation. H. influenzae: Haemophilus influenzae, P.aeruginosa: Pseudomonas 1098 
aeruginosa, S.pneumoniae: Streptococcus pneumoniae, M.catarrhalis: Moraxella catarrhalis, 1099 
K.pneumoniae: Klebsiella pneumoniae. 1100 
 1101 
e-Figure 2: Two-year mortality and exacerbation frequency of each identified clinical cluster 1102 
in both derivation and validation cohorts are not influenced by smoking status. Sankey 1103 
diagram illustrating mortality and exacerbation frequency between identified clinical clusters 1104 
partitioned by smoking status in derivation (a and b) and validation (c and d) cohorts. 1105 
Horizontal flow colors indicate the five clinical clusters: Ex-tuberculosis (green), diabetic 1106 
(blue), low co-morbidity: low-risk (violet red), low co-morbidity: high-risk (yellow) and 1107 
cardiovascular (pink). Width of flow indicates the proportion of patients within each group. 1108 
SE: severe exacerbator, Ex-TB: ex-tuberculosis, LCLR: low co-morbidity: low-risk. LCHR: 1109 
low co-morbidity: high-risk, CVS: cardiovascular 1110 
 1111 
e-Figure 3: Contour plot to determine optimal model parameter selection for Regularised 1112 
Discriminant Analysis (RDA) model used for determination of validation cluster 1113 
membership. Kernel density estimation (KDE) is represented in a density plot with marginal 1114 
distributions of gamma and lambda on the x- and y-axes respectively. Contour colour 1115 
corresponds to the probability where the optimal gamma and lambda lie (dark blue: highest 1116 
probability, light blue: lowest probability).  The optimal gamma and lambda of the 1117 
Regularised Discriminant Analysis (RDA) model were chosen from the darkest region of the 1118 
KDE plot and corresponds to gamma=0.012 and lambda=0.130. 1119 
 1120 
e-Figure 4: Decision tree generated via Classification and Regression trees (CART) for 1121 
classification of a Chinese COPD patient into one of the derived clusters. Previous 1122 
pulmonary tuberculosis was defined as a prior history of documented tuberculosis with 1123 
positive sputum analysis for mycobacteria tuberculosis including positive acid-fast bacilli 1124 
smear, culture or nucleic acid amplification, radiological features (on chest radiography or 1125 
computed tomography) and/or prior pharmacological treatment for pulmonary tuberculosis. 1126 
Diabetes mellitus was defined as the presence of either fasting blood glucose levels of ≥7.0 1127 
mmol/l, blood glucose levels of ≥11.1 mmol/l two-hour post oral glucose tolerance test, 1128 
random blood glucose level ≥11.1 mmol/l with hyperglycemia symptoms, or HbA1c ≥6.5%. 1129 
Coronary artery disease was defined based on functional testing, radiological imaging and/or 1130 
coronary angiography.  Ex-TB: ex-tuberculosis, LCLR: low co-morbidity: low-risk, LCHR: 1131 
low co-morbidity: high-risk, CVS: cardiovascular. 1132 
 1133 
e-Figure 5:  Increased systemic TNF-R2 associates with significantly greater symptoms (by 1134 
CAT score) and severe exacerbations. Median values (grey line) are illustrated. Dot color 1135 
indicates patient membership to their respective clinical cluster: Ex-tuberculosis (green), 1136 
diabetic (blue), low co-morbidity: low-risk (violet red), low co-morbidity: high-risk (yellow) 1137 
and cardiovascular (pink). CAT: COPD assessment test, SE: severe exacerbator. *p ≤ 0.05.  1138 
 1139 
e-Figure 6: Significantly higher mortality is detected in the cardiovascular followed by ex-1140 
tuberculosis, diabetic and low comorbidity high-risk cluster compared to the low comorbidity 1141 
low-risk cluster after adjustment for age, sex, BMI, smoking pack year exposure, lung 1142 
function (by FEV1) and GOLD group illustrated by forest plot with multivariate hazard 1143 
regression. The dot represents the hazard ratio with colour indicating significance levels: red 1144 
(p<0.05). Error bar indicates the 95% confidence interval (CI). Ex-TB: ex-tuberculosis, 1145 
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